CHEK1 and lung carcinoma: CHK1 inhibitor AZD7762 was significantly correlated with lepidic score, and the regulation of DNA damage and cell cycle response by the CHK1 pathway was considered to be one of the reasons for the therapeutic resistance of lung cancer.4